



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to
Lancet Oncol 2020;
21: 1023–34**

Maringe C, Spicer J, Morris M, et al. *The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.* Lancet Oncol 2020; **21**: 1023–34—In this Article, the Open Access license has been amended to CC BY. This correction has been made to the online version as of Dec 30, 2020.

**Correction to
Lancet Oncol 2020;
21: 1549–50**

Rose PG, Mahdi H. *Landmark studies of therapeutic vaccination in cervical and ovarian cancers.* Lancet Oncol 2020; **21**: 1549–50—In this Comment, on the second and eleventh lines of paragraph two, the drug name has been corrected to GX-188E. This correction has been made to the online version as of Dec 30, 2020.

**Correction to
Lancet Oncol 2020;
21: 1574–88**

Powles T, van der Heijden MS, Castellano D, et al. *Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.* Lancet Oncol 2020; **21**: 1574–88—In this Article, the affiliation for Ignacio Duran should have been Hospital Universitario Virgen del Rocío, Seville, Spain. This correction has been made to the online version as of Dec 30, 2020.

**Correction to
Lancet Oncol 2020;
21: 1602–10**

Poortmans PM, Weltens C, Fortpied C, et al. *Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.* Lancet Oncol 2020; **21**: 1602–10—In this Article, the funders of the study should have been Ligue Nationale contre le Cancer and KWF Kankerbestrijding in the Funding and Acknowledgments sections. This correction has been made to the online version as of Dec 30, 2020.

**Correction to
Lancet Oncol 2021;
22: 8–9**

Kulkarni GS. *Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?* Lancet Oncol 2021; **22**: 8–9—In this Comment, the Declaration of interests statement was incorrect and should have read as follows: “I report personal fees from Merck, Ferring, Biosynt, TerSera, AbbVie, Roche, Theralase, and Janssen, outside the submitted work”. This correction has been made to the online version as of Dec 30, 2020, and the printed version is correct.